Patient Square Capital LP Makes New $1.66 Million Investment in Arvinas, Inc. (NASDAQ:ARVN)

Patient Square Capital LP acquired a new position in shares of Arvinas, Inc. (NASDAQ:ARVN) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 86,627 shares of the company’s stock, valued at approximately $1,661,000. Arvinas makes up about 0.6% of Patient Square Capital LP’s portfolio, making the stock its 18th biggest holding. Patient Square Capital LP owned approximately 0.13% of Arvinas as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in ARVN. T. Rowe Price Investment Management Inc. acquired a new position in Arvinas in the fourth quarter valued at approximately $42,332,000. Norges Bank purchased a new stake in shares of Arvinas during the 4th quarter worth approximately $23,845,000. Boxer Capital Management LLC purchased a new stake in shares of Arvinas during the 4th quarter worth approximately $20,294,000. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Arvinas by 42.8% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,776,555 shares of the company’s stock valued at $34,057,000 after buying an additional 532,105 shares in the last quarter. Finally, Affinity Asset Advisors LLC grew its position in shares of Arvinas by 180.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 630,000 shares of the company’s stock valued at $12,077,000 after buying an additional 405,000 shares during the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Insider Buying and Selling

In other Arvinas news, insider Noah Berkowitz sold 8,658 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total transaction of $74,372.22. Following the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. The trade was a 7.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total value of $523,971.36. Following the transaction, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. This trade represents a 2.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 over the last ninety days. Corporate insiders own 4.73% of the company’s stock.

Arvinas Price Performance

Shares of NASDAQ ARVN opened at $6.29 on Wednesday. The stock has a fifty day moving average price of $8.20 and a 200 day moving average price of $16.48. Arvinas, Inc. has a 1-year low of $5.94 and a 1-year high of $37.38. The company has a market cap of $459.11 million, a PE ratio of -2.27 and a beta of 2.21.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings data on Thursday, May 1st. The company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. The business’s revenue was up 646.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.97) earnings per share. Analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARVN has been the topic of several research analyst reports. Truist Financial reiterated a “hold” rating and set a $11.00 price target (down from $21.00) on shares of Arvinas in a research note on Monday, May 5th. Guggenheim cut their target price on Arvinas from $32.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, May 2nd. Barclays reduced their target price on Arvinas from $32.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, May 2nd. TD Cowen downgraded Arvinas from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Finally, Wedbush cut Arvinas from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $57.00 to $12.00 in a research note on Wednesday, March 12th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $20.91.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.